• LAST PRICE
    0.0700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0700 / 0.0700
  • Day Range
    Low 0.0700
    High 0.0700
  • 52 Week Range
    Low 0.0131
    High 0.2999
  • Volume
    100,000
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.07
TimeVolumeINTI
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesINTI
Inhibitor Therapeutics Inc
12.0M
2.8x
---
United StatesCLCS
Cell Source Inc
12.0M
-1.7x
---
United StatesAKTX
Akari Therapeutics PLC
12.3M
-0.3x
---
United StatesPRTG
Portage Biotech Inc
11.1M
-0.1x
---
United StatesATHE
Alterity Therapeutics Ltd
17.1M
-1.1x
---
United StatesDOMH
Dominari Holdings Inc
13.1M
-0.5x
---
As of 2024-03-29

Company Information

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. It also explores acquiring or licensing other pre-clinical and clinical stage therapeutics addressing unmet needs and orphan indications for the treatment of cancer and other diseases. The Company’s primary focus is on the development of therapies initially for BCCNS, prostate and lung cancers in the United States utilizing Itraconazole, in a patent-protected formulation. It has conducted a Phase IIb study of SUBA-Itraconazole for the treatment of Basal Cell Carcinoma Nevus Syndrome, and Mayne Pharma assumed control of the clinical and regulatory development of this formulation for this indication.

Contact Information

Headquarters
4830 W. Kennedy Blvd., Suite 600TAMPA, FL, United States 33609
Phone
813-766-2462
Fax
813-527-0500

Executives

Executive Chairman of the Board, Chief Executive Officer
Francis O'Donnell
Chief Financial Officer, Treasurer, Secretary
James Mcnulty
Director
Ronald Osman
Independent Director
Michael Jerman
Independent Director
Samuel Sears

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.0M
Revenue (TTM)
$0.00
Shares Outstanding
172.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.85
EPS
$0.03
Book Value
$0.05
P/E Ratio
2.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.